NYSE$NSPR
InspireMD Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
InspireMD reported record revenue, driven by CE Mark recertification and increased stent sales. Clinical trial data showed favorable results, and the company advanced its product pipeline.
InspireMD reported a record fourth quarter with a 71.6% increase in revenue compared to the same period last year. The company's growth was driven by CE Mark recertification and increased stent sales. InspireMD also announced positive data from its C-GUARDIANS clinical trial and advancements in its product pipeline.
- Total revenue increased by 71.6% to $1.761 million compared to Q4 2022.
- Over 3,100 stents were sold, representing a 74% year-over-year increase.
- Gross profit increased by 155.1% to $505,000 compared to Q4 2022.
- Cash, cash equivalents, short-term bank deposits and marketable securities were $39.0 million as of December 31, 2023, compared to $17.8 million as of December 31, 2022.
Headline financials
Revenue & EPS history
InspireMD · Revenue · Quarterly
$1.76M
Revenue by segment
InspireMD · $1.56M total across 1 segment · Q3 2023
- CGuard EPS$1.56M+8.7%100.0%
Forward guidance
InspireMD is positioned with solutions to support CAS and TCAR procedures, with clinical and regulatory catalysts expected this year and next.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
-3.7%
Avg return
Earnings day
-7.1%
Avg return
5 days after
-12.5%
Avg return
30 days after
32%
19 / 60 earnings
Positive
+15.4%
Q4 2014
Best reaction
-26.3%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.7% | +0.0% | — | |
| Q4 2025 | +0.0% | -2.8% | -24.6% | |
| Q3 2025 | -7.0% | -21.0% | -16.2% | |
| Q1 2025 | +0.0% | -9.2% | -3.8% | |
| Q4 2024 | +0.7% | +0.4% | -8.2% | |
| Q3 2024 | +2.0% | +2.8% | +25.6% | |
| Q2 2024 | -3.4% | -3.4% | -7.4% | |
| Q1 2024 | -4.2% | -4.2% | +8.3% | |
| Q4 2023 | +0.4% | -3.0% | -12.9% | |
| Q3 2023 | -6.0% | -9.0% | -26.1% | |
| Q2 2023 | +0.0% | +3.5% | +11.9% | |
| Q1 2023 | -4.3% | -2.2% | +11.4% | |
| Q4 2022 | -1.7% | -6.1% | -9.6% | |
| Q3 2022 | -13.9% | -22.2% | +5.6% | |
| Q2 2022 | -6.3% | -5.9% | -15.1% | |
| Q1 2022 | -3.9% | +1.0% | +1.9% | |
| Q4 2021 | +4.6% | -4.6% | +19.8% | |
| Q3 2021 | -1.4% | -3.4% | -14.9% | |
| Q2 2021 | -2.5% | -4.8% | +7.8% | |
| Q1 2021 | +0.6% | -3.2% | +23.6% | |
| Q4 2020 | -11.4% | -4.9% | -20.5% | |
| Q3 2020 | +2.9% | +0.0% | +0.0% | |
| Q2 2020 | -2.1% | -2.1% | -27.7% | |
| Q1 2020 | +13.5% | +6.8% | -24.3% | |
| Q4 2019 | -22.0% | -35.4% | -18.3% | |
| Q3 2019 | -26.3% | -33.8% | -31.6% | |
| Q2 2019 | -19.9% | -18.0% | -11.4% | |
| Q1 2019 | -19.4% | -24.3% | -14.4% | |
| Q4 2018 | -10.0% | -12.5% | -46.6% | |
| Q3 2018 | -4.2% | -8.3% | -20.8% | |
| Q2 2018 | +4.8% | +4.8% | -9.5% | |
| Q1 2018 | +7.3% | -2.4% | -7.3% | |
| Q4 2017 | -1.0% | -0.8% | -41.2% | |
| Q3 2017 | +0.0% | +2.6% | -64.1% | |
| Q2 2017 | -6.3% | -16.7% | -33.3% | |
| Q1 2017 | +0.0% | -7.9% | -12.7% | |
| Q4 2016 | -9.0% | -14.5% | -59.0% | |
| Q3 2016 | -4.1% | +2.4% | +22.9% | |
| Q2 2016 | -10.5% | -15.8% | -31.6% | |
| Q1 2016 | -14.3% | — | — | |
| Q4 2015 | +2.0% | — | — | |
| Q3 2015 | -15.8% | — | — | |
| Q2 2015 | -25.0% | — | — | |
| Q1 2015 | -11.5% | — | — | |
| Q4 2014 | +15.4% | — | — | |
| Q3 2014 | -3.3% | — | — | |
| Q2 2014 | +2.1% | — | — | |
| Q1 2014 | +1.8% | — | — | |
| Q4 2013 | +2.0% | — | — | |
| Q3 2013 | -3.1% | — | — | |
| Q2 2013 | -0.9% | — | — | |
| Q1 2013 | -6.0% | — | — | |
| Q4 2012 | -8.6% | — | — | |
| Q3 2012 | +1.4% | — | — | |
| Q2 2012 | +2.1% | — | — | |
| Q1 2012 | -16.8% | — | — | |
| Q4 2011 | +9.7% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +7.7% | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro